SLCO1A2 and glioblastoma: As aforementioned, OATP1A2, 2B1, 1C1 and 4A1 immunoreactivity was identified on both myeloid cells (IBA1+ cells) and blood vessels (Lectin+) within both GBM tumor tissue and non-tumor tissue (Figure 3E–H).